Outcome of Board Meeting

& INDO US A" BIO-TECH LIMITED Indo-US (AN ISO CERTIFIED COMPANY) Agiiieeds CIN LO1122GJ2004PLC043550 Date: 30® October, 2026 BSE Limited National Stock Exchange of India Limited Dept. of Corporate Services, Dept. of Corporate Compliances, Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1 Block-G, Dalal Street, Bandra Kurla Complex, Mumbai- 400 001 Bandra (E) Mumbai- 400 051 BSE Scrip Code - 541304 NSE Symbol: INDOUS Sub: Outcome of Board Meeting held on Friday, October 30, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Ref: Indo Us Bio Tech Limited Dear Sir, Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Friday, October 30, 2026 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business: 1. The Board approved unaudited financial results of the company for the quarter/half year ended 30" September, 2026 along with limited review reports obtained from the Auditor of the Company. The Board Meeting commenced at 15:30 P.M. and concluded at 16:00 P.M. You are requested to kindly take the same on record. Thanking you, For, Indo us Bio Tech Limited DIMPY Digitall signed by DIMPY DIVYANGEHA JOSHI JDOISVHYIA NGBHAI +Da0t5e3: 02°0 26.10.30 1604550 Ms. Dimpy Joshi Company Secretary & Compliance officer | DSIR RECOGNITION IN HOUSE RAD UNIT v ry Addres: Vikage Bardioh Kanth. E-mail : indous_jagdish@yanoo.co.in *indo-us, Wob " ww indousagriseo CHARTERED ACCOUNTANTS ©B B-1204, S HoILP CORP RORoAATE PARK CAR. K. BHAGAT BODAKDEV, AHMEDABAD-380054 CA NiAl"JISH BHAGAT f( ) +9197262 57136, +91 98790 61500 7 bhagatasso@gmail.com, GO KA HIAGAT INDIA rkmbhagat@gmail.com LAl @ https://www.bhagatandassociates.org CA VAIBHAV SHINGALA INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND- AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED. LIMITED REVIEW REPORT The Board of Directors, Indo US Bio-Tech Limited, Ahmedabad, Gujarat 1. We have reviewed the accompanying standalone statement of unaudited financial results of Indo US Bio-Tech Limited (CIN: L01122GJ2004PLC043550) (the company) for the quarter ended 30th September 2026 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended (Listing Regulations). 2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34 -Interim Financial Reporting' prescribed under section 133 of the Companies Act. 2013 (the Act) read with relevant rules issued there under and other recognized accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review. CA SUNIL PATEL - 9i 6880 | patelsunilh@yahoo.co.in 3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules made thereunder and other accounting principles generally accepted in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. For, Bhagat & Associates Chartered Accountants FRN - 101100W R.K Bhagat (Partner) Membership No - 035263 UDIN: 26035263VRBIDW8856 Place: Ahmedabad Date: 30.10.2026 'INDO US ¥| BIO-TECH LIMITED Indo-US (AN ISO CERTIFIED COMPANY) Agiicesds CIN LO1122GJ2004PLCO43550 nGa US Bio-ecTh Uimiied CIN LD1122G42004PLC041550 Ad Std ar te os ms u n3 t0 9 o, f sS th aa nn dti a lM oa nll e, aS ne st ua dd in ta er d C fh ia nar n cR ia as l t ra e sO up ltp s fN oa rv r tha en g q uT ao rw ts ar r, enB do ela d R oo na d J, 0 1A h k Sm ee pd ta eb ma bd er 3 78 00 20 88 1 (Amoinu Lankhts) G Endod T vearty Vowr Frded Farimeutars SepG iu ua mrt be er T 3o 0a ,e 2d 0 26 | G uu mar ei e 3r ,E 2n 0d 2e 0d Cusrtor E 3r 0,i n 7d 0 25 il ot 30,y 2 028 i Vea 3r 0i 2y waV re ca hr 3F 1r a 2v ud inc e Rovere from Operatons 150483 12900 2084 65 e w161 61 Toere| o 489 1238 202 1726 gl sgl o 1,500 82 31108 EXTiE13 a0 5T (XCED 0 Erserses:. Frchase o s i tradn 11504 s2019 70 1,08604 v SRy [Changee s in nve noft Fionisrvedi Geonsds, Work-in- 15457 w6255 190057 1017 12 2am 52 783400 "“::—..""'" 121806 36552 1.402 67 s @4 R 204 960 eTay w5 T ol 8 Amortsation 2n 0n a 20n 73 1 56 55 04 10 o w1 a4 r1 2 92 24 23 Expamas 26090 2982 4346 545 41 a3 e Loss. Eo xcep tex ocop nuo an O iem tem = 50 30 03 13 75 0 27 33 551 3 88 9 ap 1r 51 7.8 02 8) 5 w32 a6 r n50 D T3zX 07 Tax Exoponse s i o 0770 35580 709) B Vw202 income Tax o e an o34 1629 sanr - Eartior Years Exponses (Weition back] 87 wer) 318 [Deterred Tm Charge 2:] o) 201 162 600 2161 T Fin) 396 o s 16z 2243 (%) Prost for the Yoar (367 14) ETIN7) E¥I] 867) wsas| dau [Other CompraEhxpeensness iincvomee) [A ) Noma thal wil not be rectassifiod Lo Profil and Loss 07 (4)Income tax relating 1o terms that wil not be 1r B ec sta 2s12 0 aP wroi fitf e a in md ct e nL mio idw nos d - Emp 1i yo Aye oe t B e 2n 0e 6 fi Lt o na . = % ( 56 | <- ©s - 7) 020 () ncLoax remlatineg o deras that wil nok be reclasatiod to rofi snd Loss - g 0z s 014 {0 64)) 10 43)} 10 58)) Total Comprehensiva Income o7 14) Siia a5t 5867 31502 ) [Earmings Per Equity Share (Nominai Vaiue Per [Share: R 10 (Previous Year. Ra. 1611 Basic and Dited 18] 151 172 2| 400 85 Notes (1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30th October, 2026 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results. (2) The company Is dealing in one major product segment, |.e. Seed Cullivation, processing and trading (4) The figures have been regroupedirearranged wherever necessary. (5) Investor complained - opening unresolved -NIL, Received during the quarter NIL, resolved during the quarter- NIL and balance unresolved at the end of the quarter NIL RX Bhagal Partrer of Directors | w2e033EksvRa, Sua~cKef - Managing Oirector Place DIN: 01745951 Oate: 30-10- Regd. Office 1 R&Dfarm o Processing Plant « Cold Storage 309, Shanti Mall, Sattadhar Cross Road, Opp. Navrang Tower, Ahme [Showing first 8,000 characters — download PDF for full document]